Skip to content
10-Q

Quarterly Report

ENTRADA THERAPEUTICS, INC. TRDA

0001689375-26-000028

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 38.82M sh
Shares Diluted Q1 2026 · Mar 31, 2026 41.84M sh
Shares Diluted Q1 2026 · Mar 31, 2025 41.07M sh
Capex Q1 2026 · Mar 31, 2026 $44K
Capex Q1 2026 · Mar 31, 2025 $1.14M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$41.7M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$38.51M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $76.44M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $90.39M
Stockholders Equity Q1 2026 · Mar 31, 2026 $270.85M
Stockholders Equity Q1 2026 · Dec 31, 2025 $306.13M
Stockholders Equity Q1 2026 · Mar 31, 2025 $417.26M
Stockholders Equity Q1 2026 · Dec 31, 2024 $428.68M
Current Liabilities Q1 2026 · Mar 31, 2026 $19.2M
Current Liabilities Q1 2026 · Dec 31, 2025 $24.45M
Total Liabilities Q1 2026 · Mar 31, 2026 $64.66M
Total Liabilities Q1 2026 · Dec 31, 2025 $71.25M
Current Assets Q1 2026 · Mar 31, 2026 $266.87M
Current Assets Q1 2026 · Dec 31, 2025 $306.25M
Total Assets Q1 2026 · Mar 31, 2026 $335.52M
Total Assets Q1 2026 · Dec 31, 2025 $377.38M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.95
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.42
Eps Basic Q1 2026 · Mar 31, 2026 −$0.95
Eps Basic Q1 2026 · Mar 31, 2025 −$0.42
Sga Expense Q1 2026 · Mar 31, 2026 $10.12M
Sga Expense Q1 2026 · Mar 31, 2025 $10.27M
Rd Expense Q1 2026 · Mar 31, 2026 $33.05M
Rd Expense Q1 2026 · Mar 31, 2025 $32.07M
Net Income Q1 2026 · Mar 31, 2026 −$39.72M
Net Income Q1 2026 · Mar 31, 2025 −$17.35M
Operating Income Q1 2026 · Mar 31, 2026 −$42.3M
Operating Income Q1 2026 · Mar 31, 2025 −$21.79M
Revenue Q1 2026 · Mar 31, 2026 $875K
Revenue Q1 2026 · Mar 31, 2025 $20.56M